Improving Treatments - Improving Lives

Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients. All clinical studies for Envarsus®, including two Phase III trials, have successfully been completed and a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in December 2013 seeking approval for the marketing and sale of Envarsus®. Envarsus® has been granted Orphan Drug Status by the FDA.


Apr 9, 2014
Annual General Meeting

PDF Veloxis Passing of Annual General Meeting
 262.7 KB   Add to Briefcase
PDF Veloxis convene annual general meeting
 185.7 KB   Add to Briefcase
PDF Registration Form with Proxy and Absentee Vote
 107.2 KB   Add to Briefcase
PDF Veloxis Articles of Association - draft
 467.7 KB   Add to Briefcase

Stock Information